vs
Side-by-side financial comparison of Krispy Kreme, Inc. (DNUT) and Bio-Techne (TECH). Click either name above to swap in a different company.
Krispy Kreme, Inc. is the larger business by last-quarter revenue ($392.4M vs $295.9M, roughly 1.3× Bio-Techne). Bio-Techne runs the higher net margin — 12.8% vs -7.1%, a 19.9% gap on every dollar of revenue. On growth, Krispy Kreme, Inc. posted the faster year-over-year revenue change (-2.9% vs -6.4%). Over the past eight quarters, Bio-Techne's revenue compounded faster (4.2% CAGR vs -5.9%).
Krispy Kreme, Inc. is an American multinational doughnut company and coffeehouse chain. Krispy Kreme was founded by Vernon Rudolph (1915–1973), who bought a yeast-raised recipe from a New Orleans chef, rented a building in 1937 in what is now historic Old Salem in Winston-Salem, North Carolina, and began selling to local grocery stores. Steady growth preceded an ambitious expansion as a public company in the period 2000 to 2016, which ultimately proved unprofitable. In 2016, the company retur...
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
DNUT vs TECH — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $392.4M | $295.9M |
| Net Profit | $-27.8M | $38.0M |
| Gross Margin | — | 64.6% |
| Operating Margin | -1.9% | 18.4% |
| Net Margin | -7.1% | 12.8% |
| Revenue YoY | -2.9% | -6.4% |
| Net Profit YoY | -23.8% | 68.3% |
| EPS (diluted) | $-0.18 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $392.4M | $295.9M | ||
| Q3 25 | $375.3M | — | ||
| Q2 25 | $379.8M | $317.0M | ||
| Q1 25 | $375.2M | $316.2M | ||
| Q4 24 | $404.0M | $297.0M | ||
| Q3 24 | $379.9M | $289.5M | ||
| Q2 24 | $438.8M | $306.1M | ||
| Q1 24 | $442.7M | $303.4M |
| Q4 25 | $-27.8M | $38.0M | ||
| Q3 25 | $-19.4M | — | ||
| Q2 25 | $-435.3M | $-17.7M | ||
| Q1 25 | $-33.3M | $22.6M | ||
| Q4 24 | $-22.4M | $34.9M | ||
| Q3 24 | $39.6M | $33.6M | ||
| Q2 24 | $-5.5M | $40.6M | ||
| Q1 24 | $-8.5M | $49.1M |
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% | ||
| Q1 24 | — | 67.4% |
| Q4 25 | -1.9% | 18.4% | ||
| Q3 25 | -1.9% | — | ||
| Q2 25 | -114.4% | -7.5% | ||
| Q1 25 | -5.4% | 12.2% | ||
| Q4 24 | -2.8% | 16.0% | ||
| Q3 24 | -4.2% | 13.8% | ||
| Q2 24 | 1.6% | 15.0% | ||
| Q1 24 | 2.7% | 22.1% |
| Q4 25 | -7.1% | 12.8% | ||
| Q3 25 | -5.2% | — | ||
| Q2 25 | -114.6% | -5.6% | ||
| Q1 25 | -8.9% | 7.1% | ||
| Q4 24 | -5.6% | 11.7% | ||
| Q3 24 | 10.4% | 11.6% | ||
| Q2 24 | -1.3% | 13.3% | ||
| Q1 24 | -1.9% | 16.2% |
| Q4 25 | $-0.18 | $0.24 | ||
| Q3 25 | $-0.11 | — | ||
| Q2 25 | $-2.55 | $-0.11 | ||
| Q1 25 | $-0.20 | $0.14 | ||
| Q4 24 | $-0.13 | $0.22 | ||
| Q3 24 | $0.23 | $0.21 | ||
| Q2 24 | $-0.03 | $0.26 | ||
| Q1 24 | $-0.05 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $42.4M | $172.9M |
| Total DebtLower is stronger | $911.9M | $260.0M |
| Stockholders' EquityBook value | $650.1M | $2.0B |
| Total Assets | $2.6B | $2.5B |
| Debt / EquityLower = less leverage | 1.40× | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $42.4M | $172.9M | ||
| Q3 25 | $30.7M | — | ||
| Q2 25 | $21.3M | $162.2M | ||
| Q1 25 | $18.7M | $140.7M | ||
| Q4 24 | $29.0M | $177.5M | ||
| Q3 24 | $25.4M | $187.5M | ||
| Q2 24 | $28.6M | $152.9M | ||
| Q1 24 | $33.1M | $145.3M |
| Q4 25 | $911.9M | $260.0M | ||
| Q3 25 | $906.2M | — | ||
| Q2 25 | $889.4M | $346.0M | ||
| Q1 25 | $935.0M | $330.0M | ||
| Q4 24 | $844.5M | $300.0M | ||
| Q3 24 | $804.6M | $300.0M | ||
| Q2 24 | $895.0M | $319.0M | ||
| Q1 24 | $881.8M | $389.0M |
| Q4 25 | $650.1M | $2.0B | ||
| Q3 25 | $670.3M | — | ||
| Q2 25 | $693.6M | $1.9B | ||
| Q1 25 | $1.1B | $2.0B | ||
| Q4 24 | $1.1B | $2.1B | ||
| Q3 24 | $1.2B | $2.1B | ||
| Q2 24 | $1.1B | $2.1B | ||
| Q1 24 | $1.2B | $2.0B |
| Q4 25 | $2.6B | $2.5B | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.6B | $2.6B | ||
| Q1 25 | $3.1B | $2.6B | ||
| Q4 24 | $3.1B | $2.7B | ||
| Q3 24 | $3.1B | $2.7B | ||
| Q2 24 | $3.2B | $2.7B | ||
| Q1 24 | $3.2B | $2.7B |
| Q4 25 | 1.40× | 0.13× | ||
| Q3 25 | 1.35× | — | ||
| Q2 25 | 1.28× | 0.18× | ||
| Q1 25 | 0.85× | 0.16× | ||
| Q4 24 | 0.74× | 0.14× | ||
| Q3 24 | 0.68× | 0.14× | ||
| Q2 24 | 0.79× | 0.15× | ||
| Q1 24 | 0.76× | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.0M | — |
| Free Cash FlowOCF − Capex | $27.9M | — |
| FCF MarginFCF / Revenue | 7.1% | — |
| Capex IntensityCapex / Revenue | 4.4% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-64.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.0M | — | ||
| Q3 25 | $42.3M | — | ||
| Q2 25 | $-32.5M | $98.2M | ||
| Q1 25 | $-20.8M | $41.1M | ||
| Q4 24 | $27.0M | $84.3M | ||
| Q3 24 | $3.3M | $63.9M | ||
| Q2 24 | $33.2M | $75.5M | ||
| Q1 24 | $-17.7M | $81.0M |
| Q4 25 | $27.9M | — | ||
| Q3 25 | $15.5M | — | ||
| Q2 25 | $-60.8M | $93.3M | ||
| Q1 25 | $-46.7M | $31.0M | ||
| Q4 24 | $-6.9M | $77.5M | ||
| Q3 24 | $-22.9M | $54.7M | ||
| Q2 24 | $1.6M | $57.5M | ||
| Q1 24 | $-46.8M | $64.5M |
| Q4 25 | 7.1% | — | ||
| Q3 25 | 4.1% | — | ||
| Q2 25 | -16.0% | 29.4% | ||
| Q1 25 | -12.5% | 9.8% | ||
| Q4 24 | -1.7% | 26.1% | ||
| Q3 24 | -6.0% | 18.9% | ||
| Q2 24 | 0.4% | 18.8% | ||
| Q1 24 | -10.6% | 21.3% |
| Q4 25 | 4.4% | — | ||
| Q3 25 | 7.1% | — | ||
| Q2 25 | 7.4% | 1.5% | ||
| Q1 25 | 6.9% | 3.2% | ||
| Q4 24 | 8.4% | 2.3% | ||
| Q3 24 | 6.9% | 3.2% | ||
| Q2 24 | 7.2% | 5.9% | ||
| Q1 24 | 6.6% | 5.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.82× | ||
| Q4 24 | — | 2.42× | ||
| Q3 24 | 0.08× | 1.90× | ||
| Q2 24 | — | 1.86× | ||
| Q1 24 | — | 1.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DNUT
Segment breakdown not available.
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
